news

Study presents new ways of developing chronic inflammation treatment

Researchers have found a new way to treat the inflammation involved in chronic diseases.

Researchers have found a new way to treat the inflammation involved in chronic diseases such as psoriasis, asthma and HIV. A group of transmitter substances (cytokines) in the immune system (IL-1 family), has been shown to play an important role in many of these diseases by regulating the body’s immune responses.

Professor Charles A Dinarello from the University of Colorado Denver (who discovered the important cytokine IL-1(-β), which plays an important role in countless diseases), in collaboration with researchers from Aarhus University Hospital and Aarhus University in Denmark, have investigated a more efficient way of reducing the effect of the IL-1 family and improve treatment of chronic inflammatory diseases.

In this study, the researchers investigated if a receptor (IL-1R3), which is involved in the signaling of six different inflammatory cytokines in the IL-1 family, could be a possible target in the treatment of chronic inflammatory disease.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

Using an antibody to block the effect of IL-1R3, it was possible for the researchers to investigate the effects in both studies on cells and mice.

The researchers then studied some of the consequences of blocking this receptor on the immune system. They specifically studied the effect of blocking IL-1R3 in mice with either gout, acute allergic inflammation (asthma) or psoriasis.

The experiments showed that it was possible to effectively block the receptor and reduce manifestation of diseases, which underlines the potentials in our new approach, said Jesper Falkesgaard Højen, MD, PhD.

The results were published in the scientific journal Nature Immunology.

Leave a Reply

Your email address will not be published. Required fields are marked *